Beam And Verve Benefit From Buzz Around Base-Editing Therapies
Excitement Around Next-Gen Gene-Editing
Companies claim their technologies provide more precise editing as they raise funds, but CRISPR companies remain in the lead.
You may also be interested in...
The company dosed the first patient in its study of base editor VERVE-101, a possible single-dose treatment for HeFH that joins a growing list of PCSK9-targeted therapy candidates.
Base editing has reached a new milestone as Beam’s lead candidate gets the green light for clinical trials, and its peer Verve Therapeutics is not far behind, while big pharma dips its toes in the water.
The company sees its gene-editing technology, which it compares to a DNA “word processor,” as having potentially broad applicability.